Abstract 2063P
Background
In this study we seek to learn more about the lifestyle habits of our cancer patients, with a particular emphasis in exercise and eating behaviours. We choose to focus on these two areas as they have an outsized impact on clinical outcomes such as mortality, risk of relapse, quality of life, sarcopenia, duration of hospitalizations, post-surgical complications, response to immunotherapy and even overall survival rates.
Methods
Observational study across a cross-section of cancer patients at the Medical Oncology Service of the Nuestra Señora de Candelaria University Hospital, Santa Cruz de Tenerife. The statistical significance of lifestyle habit changes is tested through a form and IPAQ, MUST, and SARC-F surveys using chi-squared tests.
Results
We involved 100 patients whose average age was 61 years. 46% of patients had lung cancer, 30% breast cancer and 10% gastrointestinal cancer. 59% patients had stage-four cancer, 48% were receiving first-line treatment and 54% were being treated with immunotherapy or target therapies. 99% of individuals considered their diet as an important pillar in their cancer disease. However, we found that only 47% had discussed aspects of their nutrition with their oncologist, but this was not statistically associated with a reduced risk of malnutrition. 80% considered that a healthy lifestyle could help reduce the adverse effects of the treatment. The validated test results showed that 45% had an intermediate-high risk of malnutrition according to the MUST test and 14% had risk of sarcopenia according to the SARC-F test. Patients receiving immunotherapy or target therapies had a higher risk of malnutrition than those receiving other treatments (50 vs 42%, p=.507). 47% were sedentary according to the IPAQ test and 80% who did not perform physical activity would start an adapted exercise program if it were available.
Conclusions
Our patients present good high-level awareness about the generally positive ways in which lifestyle changes involving healthier eating and exercise habits can impact the outcome of their treatments. However, we appreciate a need for more specific nutritional and fitness recommendations that patients can immediately put into practice, as well their ranked impact on their health.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2028TiP - Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Presenter: Julien Mazieres
Session: Poster session 06
2029TiP - Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Presenter: Sreenivasa Chandana
Session: Poster session 06
2035P - Routine biomarker monitoring does not replace comprehensive clinical assessment in the detection of immunotherapy induced myocarditis
Presenter: Alexandra Johnson
Session: Poster session 06
2036P - Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
Presenter: Weiyu Zhang
Session: Poster session 06
2037P - Prehabilitation as a strategy to improve postoperative outcomes in frail cancer patients undergoing elective surgery: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Poster session 06
2039P - Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review
Presenter: Tomonori Mizutani
Session: Poster session 06
2041P - The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
Presenter: Carmine Valenza
Session: Poster session 06
2042P - Improving breast cancer outcomes for indigenous women
Presenter: Vita Christie
Session: Poster session 06
2043P - Can Charlson Comorbidity Index (CCI) and Clinical Frailty Scale (CFS) assessments predict survival in octogenarians with colorectal cancer?
Presenter: Neda Nikolic
Session: Poster session 06
2044P - Bloodstream infections (BSI) in cancer patients: Epidemiology, antibiotic therapy and risk factors related to mortality
Presenter: Carlos López Jiménez
Session: Poster session 06